Enabling Broader Adoption Of Process Intensification In Biopharma

By Ganesh Kumar, Sartorius

PI is becoming increasingly well-understood and its utility is continuously evolving to meet specific manufacturer needs, from product development to manufacturing, whether approached stepwise or end-to-end.

The benefits of process intensification (PI) in biopharmaceutical manufacturing are well established: PI enables manufacturers to increase volumetric productivity, reduce timelines, decrease facility footprint, lower costs, or improve flexibility. However, knowledge about PI implementation — from the costs to the technological and regulatory aspects, and risk mitigation — is less ubiquitous.